Pro­tag­o­nist rais­es $22M to re­vive PTG-100; Paratek's an­tibi­ot­ic shows non-in­fe­ri­or­i­ty

→ Pro­tag­o­nist Ther­a­peu­tics {PT­GX}, a tiny pub­lic com­pa­ny in Newark, CA, has inked a se­cu­ri­ties pur­chase deal to­tal­ing $22 mil­lion in shares to sort out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.